News & Events



Press Releases



In the News



Events

SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation

RNA Delivery and Therapeutics Company SiSaf Announces Autumn Conference Schedule

SiSaf Announces Positive Preclinical Data in its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

RNA Therapeutics Company SiSaf to Present at Upcoming Conferences

SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone Disease, as Clinical Advisor

SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease

SiSaf Ltd utilizes Intoolab’s Tzager AI Platform

SiSaf Ltd Announces US$13.2 Million Series B Financing

Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epithelium

SiSaf announces licencing agreement to develop gene therapy for rare bone disease

SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research

SiSaf Establishes Strategic Partnership with Avellino Labs

SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation

RNA Delivery and Therapeutics Company SiSaf Announces Autumn Conference Schedule

SiSaf Announces Positive Preclinical Data in its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

RNA Therapeutics Company SiSaf to Present at Upcoming Conferences

SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone Disease, as Clinical Advisor

SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease

SiSaf Ltd utilizes Intoolab’s Tzager AI Platform

SiSaf Ltd Announces US$13.2 Million Series B Financing

Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epithelium

SiSaf announces licencing agreement to develop gene therapy for rare bone disease

SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research

SiSaf Establishes Strategic Partnership with Avellino Labs

Delivering RNA Therapeutics through Silicon Stabilized Hybrid Lipid Nanoparticles

November 21, 2022

VIEW ARTICLE

Delivering a New “Post-COVID” Generation of RNA Therapeutics

October 14, 2022

VIEW ARTICLE

SiSaf to seek FDA Orphan Drug Designation for SIS-101-ADO

October 13, 2022

VIEW ARTICLE

SiSaf takes steps with FDA for RNA therapeutic to treat rare genetic skeletal disorders

October 12, 2022

VIEW ARTICLE

SiSaf reveals positive preclinical data in siRNA program to treat osteopetrosis

September 12, 2022

VIEW ARTICLE

The challenges and trends of cell & gene therapies

September 6, 2022

VIEW ARTICLE

Sisaf to move siRNA program for bone growth disorder into the clinic

November 11, 2021

VIEW ARTICLE

SiSaf Exercises Option to License Gene Therapy for Rare Bone Disease

November 4, 2021

VIEW ARTICLE

Non-Viral Gene Therapies Get €51M Boost

October 4, 2021

VIEW ARTICLE

Croda International agrees new commercial arrangement with SiSaf

August 2, 2018

VIEW ARTICLE

Delivering RNA Therapeutics through Silicon Stabilized Hybrid Lipid Nanoparticles

November 21, 2022

VIEW ARTICLE

Delivering a New “Post-COVID” Generation of RNA Therapeutics

October 14, 2022

VIEW ARTICLE

SiSaf to seek FDA Orphan Drug Designation for SIS-101-ADO

October 13, 2022

VIEW ARTICLE

SiSaf takes steps with FDA for RNA therapeutic to treat rare genetic skeletal disorders

October 12, 2022

VIEW ARTICLE

SiSaf reveals positive preclinical data in siRNA program to treat osteopetrosis

September 12, 2022

VIEW ARTICLE

The challenges and trends of cell & gene therapies

September 6, 2022

VIEW ARTICLE

Sisaf to move siRNA program for bone growth disorder into the clinic

November 11, 2021

VIEW ARTICLE

SiSaf Exercises Option to License Gene Therapy for Rare Bone Disease

November 4, 2021

VIEW ARTICLE

Non-Viral Gene Therapies Get €51M Boost

October 4, 2021

VIEW ARTICLE

Croda International agrees new commercial arrangement with SiSaf

August 2, 2018

VIEW ARTICLE

2nd Annual mRNA-Based Therapeutics Summit Europe
Berlin

January 24 – 26, 2023

Attending:
Dr Suzanne Saffie-Siebert, CEO

VIEW EVENT

JPM 2023 41st Annual Healthcare Meeting
San Francisco

January 9 – 12, 2023

Attending:
Dr Suzanne Saffie-Siebert, CEO
Richard Scarrott, CFO

VIEW EVENT

BIO-Europe
Berlin

October 24 – 26, 2022

Attending:
Dr Michael Welsh, CSO
Dr Spiros Servos, BD

VIEW EVENT

RNA Leaders USA Congress
Boston

October 18 – 19, 2022

Attending:
Dr Suzanne Saffie-Siebert, CEO
Richard Scarrott, CFO

VIEW EVENT

ARM Cell & Gene Meeting
on the Mesa

October 11 – 13, 2022

Attending:
Dr Spiros Servos, BD

VIEW EVENT

JPM 2023 41st Annual Healthcare Meeting
San Francisco

January 9 – 12, 2023

Attending:
Dr Suzanne Saffie-Siebert, CEO
Richard Scarrott CFO

VIEW EVENT

BIO-Europe

October 24 – 26, 2022

Attending:
Dr Michael Welsh, CSO
Dr Spiros Servos, BD

VIEW EVENT

RNA Leaders USA Congress

October 18 -19, 2022

Attending:
Dr Suzanne Saffie-Siebert, CEO
Richard Scarrott, CFO

VIEW EVENT

ARM Cell & Gene Meeting on the Mesa

October 11 – 13, 2022

Attending:
Dr Spiros Servos, BD

VIEW EVENT